GleamWall
中文EN

COYA Coya Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1835022 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.6%
TTM net income YoY-63.7%
TTM EPS YoY-25.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-675.3%
Net margin-643.5%
FCF margin—
EBITDA margin-675.0%

Returns

ROE-99.2%
ROA-84.6%
ROIC (approx.)—
Asset turnover0.13x

Leverage & solvency

Liabilities / assets14.6%
Debt / equity0.00x
Current ratio7.24x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-23.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$234,134$243,745$251,147$3.96M$3.56M$163,616$257,884$1,952
R&D expense$8.57M$5.03M$4.10M$4.94M$2.92M$3.66M$5.21M$1.94M
SG&A expense$2.59M$2.26M$3.78M$3.27M$2.56M$2.91M$2.71M$2.14M
Operating income-$10.95M-$7.05M-$7.64M-$6.03M-$2.43M-$6.41M-$7.68M-$4.08M
Pretax income-$10.62M-$6.64M-$7.21M-$5.71M-$2.12M-$6.09M-$7.31M—
Income tax—————$0——
Net income-$10.62M-$6.64M-$7.21M-$5.71M-$2.12M-$6.09M-$7.31M-$2.92M
EBITDA-$10.95M-$7.04M-$7.64M-$6.02M-$2.43M-$6.41M-$7.67M-$4.07M
EPS (basic)-0.45-0.28-0.32—-0.13-0.36-0.44—
EPS (diluted)-0.45-0.28-0.32—-0.13-0.36-0.44—
Weighted avg. shares (diluted)23.46M23.46M22.64M—16.73M16.72M16.72M—
Balance sheet
Cash & equivalents$35.80M$43.18M$50.72M$46.82M$28.13M$29.76M$35.53M$38.34M
Current assets$39.07M$47.06M$53.26M$49.94M$32.02M$33.43M$38.37M$44.31M
PP&E, net$2,807$5,614$8,420$11,227$18,068$24,908$31,748$38,588
Total assets$39.32M$47.31M$53.27M$49.95M$32.04M$33.45M$38.40M$44.35M
Current liabilities$5.39M$3.51M$3.55M$5.87M$3.67M$4.50M$4.34M$3.82M
Total liabilities$5.75M$4.03M$4.30M$6.92M$4.76M$5.14M$5.04M$4.77M
Shareholders' equity$33.57M$43.28M$48.97M$43.03M$27.28M$28.31M$33.37M$39.58M
Shares outstanding23.46M23.46M23.46M20.93M16.74M16.72M16.72M16.71M
Cash flow statement
Operating cash flow-$7.24M-$7.38M-$6.21M-$1.01M-$1.13M-$5.77M-$2.83M-$2.41M
Investing cash flow-$23,240-$1,656-$885,000-$648,606———$0
Financing cash flow-$120,441-$166,069$11.00M$20.35M$19,137$0$19,137$9.69M
Depreciation & amortization$2,807$2,807$2,807$6,841$6,840$6,840$6,840$6,840
Stock-based compensation$910,076$943,911$2.20M$1.10M$1.07M$1.04M$1.08M$790,549

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.